Company Profile
Purple Biotech Stock Price, News & Analysis
- Ticker:
- PPBT
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- Israel
Stock performance
1.41 USD (-6.00%)
Close
Last updated: August 6, 2026
2.81M USD
Market cap
Why the stock is moving
The latest monitored company update is “Purple Biotech Reports Second Quarter 2026 Financial Results.” The corresponding closing-price reaction is not yet available.
Company overview
Next-Generation Immuno-Oncology Platform
Purple Biotech develops next-generation immunotherapies designed to increase antitumor activity while limiting toxicity. Its CAPTN-3 platform consists of masked trispecific antibodies that simultaneously target tumors and activate T cells and natural killer cells.
IM1240 Trispecific Antibody
IM1240 is a capped CD3 × 5T4 × NKG2A trispecific antibody. In patient-derived tumor samples, it demonstrated activity in treatment-resistant settings, including head and neck squamous cell carcinoma resistant to PD-1 therapy or PD-1 plus chemotherapy and bladder cancer resistant to enfortumab vedotin plus PD-1 therapy.
Conditional Immune Activation
CAPTN-3 molecules are designed to remain masked outside the tumor microenvironment and become activated at the disease site. This approach seeks to combine T-cell and NK-cell engagement while reducing systemic immune toxicity.
Existing Clinical Assets
Purple Biotech also owns clinical-stage programs including CM24 and NT219, although further development depends on external partnership or investment. Current value creation is increasingly centered on CAPTN-3, IM1240, and the design of additional trispecific combinations.
Future catalysts
Purple Biotech’s catalysts are oncology programs and any update that shows the platform can still generate differentiated data. The company remains highly data-dependent.
Recent news
- 01
Purple Biotech Reports Second Quarter 2026 Financial Results
Source: Purple Biotech
- 02
- 03
Purple Biotech Reports First Quarter 2026 Financial Results and Business Highlights
Source: Purple Biotech
- 04
Purple Biotech Announces New Data from CAPTN-3 Platform Tri-specific IM1240
Source: Purple Biotech
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Purple Biotech (PPBT)?
Purple Biotech (PPBT) most recently closed at 1.41 USD, a -6.00% move versus the previous session.
What is the market cap of Purple Biotech (PPBT)?
Purple Biotech currently has a market capitalization of 2.81M USD on BioPharmSignal.
What does Purple Biotech do?
Next-Generation Immuno-Oncology Platform Purple Biotech develops next-generation immunotherapies designed to increase antitumor activity while limiting toxicity. Its CAPTN-3 platform consists of masked trispecific antibodies that simultaneously target tumors and activate T cells and natural killer cells. IM1240 Trispecific Antibody IM1240 is a capped CD3 ×...
On which exchange is PPBT stock listed?
Purple Biotech (PPBT) is associated with NASDAQ, Israel, Biopharma.
What is CAPTN-3?
Its CAPTN-3 platform consists of masked trispecific antibodies that simultaneously target tumors and activate T cells and natural killer cells.
Which conditions is Purple Biotech targeting with CAPTN-3?
Purple Biotech is associated with oncology, cancer therapeutics based on its company overview and current catalyst commentary.
How does Purple Biotech describe recent progress with CAPTN-3?
Purple Biotech’s catalysts are oncology programs and any update that shows the platform can still generate differentiated data. The company remains highly data-dependent.
What is PD-1?
In patient-derived tumor samples, it demonstrated activity in treatment-resistant settings, including head and neck squamous cell carcinoma resistant to PD-1 therapy or PD-1 plus chemotherapy and bladder cancer resistant to enfortumab vedotin plus PD-1 therapy.